Study guide
4.4 Protocol Review, Operational Feasibility & Institutional Approvals
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
4.4 Protocol Review, Operational Feasibility & Institutional Approvals
Key Takeaways Explain This Topic AI
Comprehensive protocol review by the multidisciplinary site team identifies operational bottlenecks, patient recruitment hurdles, and execution risks before IRB submission.
Protocol complexity factors—including invasive biopsies, complex pharmacokinetics, narrow visit windows, and restrictive inclusion/exclusion criteria—substantially increase protocol deviation rates and participant dropout.
Institutional committee approvals often run in parallel or sequence with IRB review, including Scientific Review Committees (SRC), Radiation Safety Committees (RSC), Institutional Biosafety Committees (IBC), and Pharmacy & Therapeutics (P&T) / Clinical Research Pharmacy committees.
Gene therapy, viral vectors, and genetically modified organisms require mandatory Institutional Biosafety Committee (IBC) review under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.
Translating the protocol into study-specific workflows, source document templates, visit checklists, and Standard Operating Procedures (SOPs) minimizes operational deviations and ensures protocol fidelity.
Last updated: October 2026
Protocol Review, Operational Feasibility & Institutional Approvals
Operational Standard: A clinically valid protocol is meaningless if it cannot be executed cleanly at the site level. Operational feasibility requires the multidisciplinary research team to deconstruct the protocol's Schedule of Activities (SoA) , identify clinical bottlenecks, assess patient burden, navigate specialized institutional review committees, and engineer robust, study-specific workflows prior to enrolling the first subject.
On the ACRP-CP examination, questions frequently test an investigator's or coordinator's ability to identify operational risks in protocol design, anticipate non-IRB institutional committee approvals (such as Biosafety and Radiation Safety), and establish Standard Operating Procedures (SOPs) that prevent systematic protocol deviations.
1. Multidisciplinary Protocol Deconstruction
Protocol operational review is not solely the responsibility of the Principal Investigator. A comprehensive review requires input from every functional stakeholder who will touch the patient, the data, or the investigational product. ┌───────────────────────────────────────────────────────────────────────────┐
- │ MULTIDISCIPLINARY REVIEW TEAM │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ • Principal Investigator / Sub-Is: Clinical safety, eligibility & visits │
- │ • Clinical Research Coordinator (CRC): Schedule of Activities & logistics│
- │ • Research Nurse / Infusion Staff: Dosing routes, timing & toxicity rules│
- │ • Investigational Pharmacist: Formulation, stability & reconstitution │
- │ • Research Laboratory Tech: PK processing, centrifugation & cold storage │
- │ • Regulatory Coordinator: Institutional committee pathways & consent text│
- │ • Financial / Billing Analyst: Medicare Coverage Analysis & budgeting │
- └───────────────────────────────────────────────────────────────────────────┘
- The Schedule of Activities (SoA) Matrix Review
The Schedule of Activities (also termed the Schedule of Assessments) is the operational heart of the protocol. Reviewing the SoA requires cross-referencing every row against clinic workflows: ┌────────────────────────────────────────────────────────────────────────────────────────┐
- │ SAMPLE SCHEDULE OF ACTIVITIES (SoA) │
- ├──────────────────────────┬───────┬───────┬───────┬───────────┬───────────┬─────────────┤
- │ Protocol Procedure │ SCR │ Day 1 │ Day 8 │ Day 15±1d │ Day 28±2d │ EOT / Early │
- ├──────────────────────────┼───────┼───────┼───────┼───────────┼───────────┼─────────────┤
- │ Informed Consent │ X │ │ │ │ │ │
- │ Demographics & History │ X │ │ │ │ │ │
- │ Inclusion/Exclusion │ X │ X │ │ │ │ │
- │ Physical Exam & Vitals │ X │ X │ X │ X │ X │ X │
- │ 12-Lead Triplicate ECG │ X │ X │ │ X │ │ X │
- │ Safety Labs (CBC/CMP) │ X │ X │ X │ X │ X │ X │
- │ Serial PK Draws (0-12h) │ │ X │ │ X │ │ │
- │ Tumor Biopsy (Mandatory) │ X │ │ │ X │ │ X │
- │ IP Administration │ │ X │ X │ X │ X │ │
- │ ePRO / Quality of Life │ │ X │ │ X │ X │ X │
- │ Adverse Event Review │ X │ X │ X │ X │ X │ X │
- └──────────────────────────┴───────┴───────┴───────┴───────────┴───────────┴─────────────┘
- 2. Identifying Protocol Bottlenecks & Patient Burden
During operational feasibility assessment, the study team must identify operational friction points that jeopardize compliance, subject retention, and data integrity.
Major Operational Bottleneck Categories
Bottleneck Category Operational Risk & Friction Point Mitigation Strategy
Narrow Visit Windows Protocol specifies tight visit windows (e.g., Day 15 ± 1 day 15 \pm 1\text{ day} 15 ± 1 day ) that coincide with weekend clinic closures or holiday periods. Request protocol clarification/amendment for ± 2 \pm 2 ± 2 or ± 3 day \pm 3\text{ day} ± 3 day windows; establish weekend on-call research staffing.
Invasive & Sequential Procedures Mandatory serial biopsies (e.g., pre-dose and on-treatment tumor core biopsies) or serial lumbar punctures create patient resistance and procedure scheduling backlogs. Coordinate dedicated procedural slots with interventional radiology; establish clear subject compensation and procedural analgesia protocols.
Intensive Pharmacokinetics (PK) PK curves requiring serial blood draws at pre-dose, 15m, 30m, 1h, 2h, 4h, 6h, 8h, and 12h post-dose overwhelm standard outpatient clinic schedules. Utilize dedicated Phase I clinical research units equipped with infusion recliners, indwelling intravenous catheters, and immediate centrifuge access.
Questionnaire / ePRO Fatigue Mandating that subjects complete multiple lengthy quality-of-life questionnaires (100+ questions) prior to physician exam at every visit. Sequence questionnaires on ePRO tablets while the subject is in the waiting room prior to clinical examinations; provide technical support.
Complex Eligibility Criteria Highly restrictive exclusionary thresholds (e.g., absolute neutrophil count > 1.5 × 10 9 / L >1.5 \times 10^9/\text{L} > 1.5 × 1 0 9 / L , total bilirubin < 1.0 × ULN <1.0 \times \text{ULN} < 1.0 × ULN , washouts > 28 days >28\text{ days} > 28 days ) that eliminate otherwise viable candidates. Engage sponsor medical monitor during feasibility to request protocol clarifications or scientifically justified threshold adjustments.
3. The Institutional Approval Ecosystem Beyond the IRB
While Institutional Review Board (IRB) approval is universally recognized, academic medical centers, hospital health systems, and research institutes require specialized institutional committee approvals that operate in parallel or sequence with the IRB. ┌───────────────────────────────────────────────────────────────────────────┐
- │ SPECIALIZED INSTITUTIONAL APPROVAL COMMITTEES │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. Scientific Review Committee (SRC / PRMC) │
- │ • Evaluates scientific merit, study design & competing trial clash │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. Institutional Biosafety Committee (IBC) │
- │ • Mandatory for recombinant DNA, viral vectors, gene therapy & CAR-T │
- │ • Regulated under NIH Guidelines for Recombinant Research │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 3. Radiation Safety Committee (RSC / RDRC) │
- │ • Evaluates research-only radiation exposure (PET, CT, radio-labeled) │
- │ • Determines cumulative radiation dosimetric risk to participants │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 4. Pharmacy & Therapeutics (P&T) / Investigational Drug Services (IDS) │
- │ • Evaluates institutional drug formulary, hazardous handling & storage│
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 5. Information Security & IT Governance │
- │ • Reviews cloud storage, EHR interfaces, DHT cybersecurity & HIPAA │
- └───────────────────────────────────────────────────────────────────────────┘
- Institutional Biosafety Committee (IBC) Deep-Dive
Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules , any trial involving human gene transfer, genetically modified organisms, viral vectors (e.g., AAV, lentivirus, retrovirus), or live viral oncolytic agents must receive formal IBC approval .
Composition: The IBC must comprise experts in recombinant DNA technology, biological safety officers (BSOs), and independent community members representing public health interests.
Operational Scope: Inspects pharmacy laminar flow biosafety cabinets (Class II Type B2), personal protective equipment (PPE), containment facilities (BSL-2 / BSL-2+), spill response kits, and biohazard waste disposal protocols.
Radiation Safety Committee (RSC)
Under federal and state nuclear regulatory standards, any protocol that mandates radiation exposure beyond standard clinical care (e.g., serial chest CTs, 18 F {}^{18}\text{F} 18 F -FDG PET scans, DEXA body composition scans, or radio-immunotherapy) requires RSC dosimetric calculation and approval . The RSC ensures that total body and organ-specific radiation doses remain within acceptable annual occupational/research thresholds and that standardized risk language is incorporated into the informed consent document.
4. Translating Protocols into Operational Tools & SOPs
To ensure flawless execution and minimize human error, the site research team must translate the dense, multi-hundred-page protocol into practical, point-of-care operational tools. ┌───────────────────────────────────────────────────────────────────────────┐
- │ STUDY-SPECIFIC OPERATIONAL TOOLKIT │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ • Source Document Worksheets: Step-by-step visit templates with tick-boxes│
- │ • Protocol Visit Window Calculators: Dynamic spreadsheets for dates │
- │ • Blood Processing & Lab Flowsheets: Tube color order, spin speeds & -80C│
- │ • Investigational Drug Dosing Verification Sheets: Dual-nurse check tools│
- │ • Emergency Unblinding & Serious Adverse Event Contact Cards │
- │ • Study-Specific Standard Operating Procedures (SOPs) │
- └───────────────────────────────────────────────────────────────────────────┘
- Study-Specific Standard Operating Procedures (SOPs)
Where an institutional SOP provides broad guidance, a Study-Specific SOP (SSOP) provides granular, step-by-step instructions for unique protocol procedures:
Biological Specimen Chain-of-Custody: Step-by-step instructions for transporting fresh tumor biopsies from the operating suite to pathology on wet ice within 15 minutes of resection.
Emergency Code Break / Unblinding Protocol: Detailed flowchart specifying when emergency unblinding is clinically warranted, who is authorized to initiate it in the IRT, and how the PI must document the event.
Decentralized / Remote Visit Procedures: Standardized workflows for dispatching mobile research nurses, handling home drug delivery, and collecting remote electronic vital signs.
Realistic Clinical Scenario: Operational Feasibility in Cell Therapy
Scenario: A comprehensive cancer center is evaluating a Phase I trial involving an autologous CAR-T cell therapy for relapsed/refractory multiple myeloma. The protocol specifies:
Leukapheresis collection of patient peripheral blood mononuclear cells.
Viral vector transduction utilizing a replication-incompetent lentivirus.
Lymphodepleting chemotherapy (fludarabine + cyclophosphamide) for 3 consecutive days.
Intravenous CAR-T cell infusion followed by mandatory inpatient hospitalization for 14 days to monitor for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) .
Pre-dose and daily post-infusion serum cytokine biomarker draws with immediate 1-hour laboratory processing and -80°C freezing.
Operational Feasibility & Approval Mapping:
Institutional Approvals Required:
Scientific Review Committee (SRC): Validates the scientific rationale and verifies no conflict with ongoing myeloma trials.
Institutional Biosafety Committee (IBC): Mandatory review due to the lentiviral vector; inspects cell processing laboratory biosafety hoods and containment protocols.
Institutional Review Board (IRB): Evaluates risk/benefit, participant consent, and vulnerable patient protections.
Pharmacy & Therapeutics (P&T): Builds inpatient EHR electronic order sets for lymphodepleting chemotherapy and ensures immediate bedside availability of tocilizumab (IL-6 receptor antagonist) for emergent CRS treatment.
Operational Workflow Engineering:
The study team partners with the inpatient bone marrow transplant unit to reserve dedicated research beds.
A study-specific nursing flowsheet is programmed into the EHR to mandate Q4H neuro-checks using the standardized ICE (Immune Effector Cell-Associated Encephalopathy) score.
The research lab coordinates with the inpatient floor for immediate runner transport of daily cytokine blood samples to the centrifuge within 30 minutes of collection.